Management Council

Umang Vohra has been Managing Director and Global Chief Executive Officer (MD &GCEO) of Cipla since September 2016. Umang joined Cipla in October 2015 as its Global Chief Financial Officer, and from January 2016 to August 2016 was Cipla’s Global Chief Operating Officer.

After gaining degrees in engineering, marketing and finance, Umang was associated with companies such as Eicher Motors and PepsiCo. Prior to joining Cipla, Umang was Head of the North America business for Dr. Reddy’s Laboratories. Through his previous roles in India and the USA, he has built a distinguished career spanning almost two decades with deep understanding and experience in various aspects of the global pharmaceutical business.

Under Umang’s leadership, Cipla has built strong momentum in its home markets, augmented its capability, strengthened its core, and shown significant improvement in its operating margin and profitability. At the helm of the Management Council of Cipla, Umang’s big-picture agenda is to define and execute Cipla’s strategic growth roadmap and geographical footprint, identify the next levers of growth, invest in innovation for the future, and build the right organisation. Recognised as an action-oriented industry leader, Umang is a firm believer in the power of agile business models, disruptive technologies, data-driven analytics and a future-ready workforce with a view to shaping the healthcare ecosystem and making a difference to the lives of patients.

Kedar Upadhye has been President and Global Chief Financial Officer of Cipla since July 2020, heading its Global Finance and Information Technology functions. Prior to joining Cipla, Kedar was Vice President, Finance, and Head of Investor Relations at Dr. Reddy’s Laboratories. He has previously worked with Pepsi India and the Thermax Group. Kedar is a qualified Cost Accountant and Company Secretary, and an alumnus of the Indian Institute of Management, Bangalore.

Kedar is a dynamic people leader with strong domain expertise and thorough understanding of the global pharmaceutical industry. At Cipla, Kedar provides leadership and strategic oversight to multi-locational finance teams operating throughout the globe. He has spearheaded several high-impact organisation-wide projects and practices to enable strategic business partnering, drive efficiencies, cost improvements, analytics, automation, and best practice in governance. Kedar has played a key role in the improvement in the operating margin and profitability of the company in the last three years.

As a member of the Management Council of Cipla, Kedar is an integral part of decisions on identifying levers of growth, strategic acquisitions and divestments, and cost optimisation projects.

In 2018, Kedar was awarded the IMA India CFO Award for Excellence in Cost Management in recognition of the significant improvements and sustainability of practices made in Supply Chain, Operations, General & Administrative spends and various other workstreams. Under his leadership, the Company has been recognised for strengthening its governance practices through the Golden Peacock Award for Excellence in Corporate Governance 2018 by the Institute of Directors, India; the 18th ICSI National Award for Excellence in Corporate Governance from the Institute of Company Secretaries of India; and ranked second for voluntary disclosures on the India Disclosure Index 2018 by FTI Consultants.

Geena Malhotra has been President and Global Head – Manufacturing Operations. She is also leading the Devices and Diagnostics Centre of Excellence at Cipla. Geena has played a key role in leading and driving our Respiratory Innovation Engine. Under her leadership, the team has launched many flagships products across global markets which has strengthened our leadership role in the respiratory domain.

Prior to this role, Geena was Global Head of Integrated Product Development of Cipla from 2013 to 2018. Geena Malhotra completed her Bachelors in Pharmacy in 1985 from Mumbai, and received her Executive MBA degree from Washington University, St. Louis in 2017.

Having joined Cipla in 1986, for well over three decades now, Geena has been a pillar of Research and Development at Cipla. Geena spearheaded Cipla’s use of cutting-edge technology platforms, equipment, drug-device combinations, targeted drug delivery dosage forms in order to fulfill unmet patient needs. Geena has to her credit, a large number of patents in the areas of formulation development and technology in solid oral dosage forms, topical delivery systems and inhalation medical devices. Geena has provided technical leadership to multi-disciplinary Research and Development (R&D) teams within a cross-functional environment to build and deliver a high throughput R&D with technology being the core focus.

As a member of the Management Council of Cipla, Geena’s priorities are Operational Excellence, Environment, Health & Safety Management, implementation of Good Engineering Practices & Process Efficiency and reimagining operations in the digital world.

She is a recipient of the ‘Eminent Researcher Award’ by the Indian Pharmaceutical Association in 2007. FDD Express Pharma Award for Outstanding Achievement in Formulation Development and Drug Delivery in 2017. She has been also honoured by “Indian Glory Award” in 2017 by Indian Friendship Society & “Bharat Ratna Dr. APJ Abdul Kalam Excellence Award” in 2018 for outstanding & distinguished services to the nation.

Dr. Ranjana Pathak is President - Global Quality, Medical Affairs and Pharmacovigilance at Cipla, has been associated with the organisation for nearly six years. Ranjana has previously held leadership roles in pharmaceutical companies such as Actavis, Endo Pharmaceuticals, Zenith Goldline and Thames Pharmacol.

Ranjana has a Doctorate in Health Administration from the University of Phoenix, USA; an MBA from Dowling College, New York; a Post-Graduate Diploma in Pharmaceutical & Chemical Analysis from Sophia College, Mumbai; and a B.Sc. (Hons) in Chemistry from Mithibai College, Mumbai. She has received training in leadership in pharmaceuticals and biologics at Harvard University.

As a Member of the Management Council at Cipla, Ranjana leads the organisation’s worldwide quality enterprise right from the development of a product to its commercialization, and spearheads Cipla’s commitment to an uncompromising state of control with absolute regulatory compliance across all manufacturing sites of Cipla, its partners and third parties

An industry veteran, Ranjana has over three decades of experience in pharma and brings to the table extensive industry experience in dealing with regulatory bodies around the world. In 2006, Ranjana received the Rising Star award from the Healthcare Business Association. In 2018, she was recognized as Woman Leader of the Year award at the Future Leaders’ Summit. A globally-recognized subject matter expert in pharma quality today, Ranjana has several publications and lectures on the topic to her credit. She is frequently invited as a speaker and panelist to prestigious conferences organized by the International Society for Pharmaceutical Engineering (ISPE), Parenteral Drug Association (PDA), the Indian Drug Manufacturers’ Association (IDMA), the Pharmaceutical Training International (PTI), among others.

Dr. Raju Mistry has been President and Global Chief People Officer of Cipla since April 2019.

Raju is an accomplished and veteran HR leader with over 27 years of global experience across diverse sectors such as Chemicals, Pharma, FMCG, IT, Engineering and textiles. Prior to Cipla, Raju was Chief Human Resources Officer at Jubilant Life Sciences Ltd. Raju has previously worked with the Aditya Birla Group, Tata Sons, Colgate Palmolive, Siemens, and Mastech Corporation, Canada.

At Cipla, Raju oversees Human Resources, and Administration and Facilities Management.As a member of the Management Council of Cipla, Raju brings to the table her gravitas andexpertise to lead Cipla’s dynamic and ambitious people agenda with a keen focus oncorporate culture, talent, employer brand and leadership development.

Paul Miller is the Chief Executive Officer of Cipla, South Africa. He joined Cipla Medpro in 2013, prior to which he served as the Vice President and Managing Director of Mylan in South Africa and as the Marketing Director of AstraZeneca in China. 

With an MBA from the University of Wales, Paul has worked across Europe, Asia and North America before serving in leadership roles in South Africa. He brings with him more than two decades of experience of successfully building and launching innovative brands that became market leaders across therapeutic areas such as cardiovascular, gastrointestinal, respiratory and anesthesia. 

Paul is highly regarded as someone who has solid understanding of strategy, building businesses and developing people. Paul is currently spearheading the SAGA region, which comprises South Africa, Sub-Saharan Africa, Uganda (Cipla QCIL) and Cipla Global Access.  He’s driving the company’s steady growth momentum in the South African market, considered to be a second home market for Cipla globally. 

In his spare time, Paul enjoys competing in triathlons.

Pradeep Bhadauria is the President and Chief Scientific Officer (CSO) at Cipla. He joined the organization in 2020, prior to which he served as CSO and member of the Executive Committee at Amneal Pharmaceutical Inc. Pradeep has also held leadership positions in Apotex, Allergan/Actavis, Watson Pharmaceuticals, Sandoz, and Ranbaxy. With over two decades of experience, Pradeep is an industry veteran with expertise in the area of Pharmaceutical Research and Development.

With a Masters’ degree in Pharmacy from Birla Institute of Technology, Pradeep has a successful track record of developing and filing numerous products, including many first-to-file and first-to-market opportunities. He has worked on multiple dosage forms, and has extensive experience in working on complex generics, 505(B)2, specialty and other difficult-to-formulate products. He also holds several patents and has published research in various publications. 

In his current role, and as member of Management council of Cipla, Pradeep leads Cipla’s Global Integrated Product Development (IPD) organization to strengthen the company’s position as an innovation led generic and specialty pharmaceutical organization.

Swapn Malpani is the Joint President & Global Head of Supply Chain & Procurement of Cipla. He joined Cipla in 2016, prior to which he worked with leading Indian and multi-national companies across diverse sectors like pharmaceutical, medical devices, consumer and food industries; like Glenmark, Johnson & Johnson, ThermoFisher, Dr Reddys and Mars Inc. 

An engineering gold medallist and postgraduate in Supply Chain Management, Swapn brings with him 25 years of global experience and domain expertise in end-to-end Supply Chain Management & Procurement encompassing areas of strategic sourcing & procurement, external manufacturing, demand & supply planning, logistics & distribution, and customer service.

A strong leader with a strategic and creative mind set, Swapn has a proven track record of supporting the growth of organizations by championing transformation, building talent and creating tangible values. 

Achin Gupta has been Chief Executive Officer of Cipla India Business since August 2021. He spearheads Cipla’s One India strategy, leveraging synergies across prescription, generics and consumer health business.

Achin holds a M Tech degree from IIT Delhi, specializing in Biochemical Engineering and Biotechnology and an MBA from IIM, Ahmedabad. In over two decades of his career, Achin has built a strong track record as an entrepreneurial leader, establishing new businesses across markets in India, Europe and emerging markets.

Prior to joining Cipla, he was associated with Glenmark Pharmaceuticals as EVP Business Head EMEA L. Achin was a Member of the Core Operating Group, Director on the Board of key European affiliates and a Member of Board at Medicines for Europe. In his earlier roles, Achin has worked for Abbott EPD and started his career with management consulting firm AT Kearney. In addition to being an accomplished commercial leader, he brings an in depth understanding of cross functional areas including strategy, portfolio, product development, licensing and partnerships.

Achin is a sports enthusiast, and his personal favourites include cricket, tennis, and squash.